Journal
ISCIENCE
Volume 26, Issue 9, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.isci.2023.107681
Keywords
-
Categories
Ask authors/readers for more resources
This study found that BUB1 kinase is over-expressed in taxane resistant prostate cancer and a specific BUB1 kinase inhibitor can overcome this resistance. The study also found that androgen receptor variant AR-V7 can increase BUB1 levels and reduce sensitivity to taxanes.
Men with incurable castration resistant prostate cancer (CRPC) are typically treated with taxanes; however, drug resistance rapidly develops. We previously identified a clinically relevant seven gene network in aggressive CRPC, which includes the spindle assembly checkpoint (SAC) kinase BUB1. Since SAC is deregulated in taxane resistant PC, we evaluated BUB1 and found that it was over-expressed in advanced PC patient datasets and taxane resistant PC cells. Treatment with a specific BUB1 kinase inhibitor re-sensitized resistant CRPC cells, including cells expressing constitutively active androgen receptor (AR) variants, to clinically used taxanes. Consistent with a role of AR variants in taxane resistance, ectopically expressed AR-V7 increased BUB1 levels and reduced sensitivity to taxanes. This work shows that disruption of BUB1 kinase activity reverted resistance to taxanes, which is essential to advancing BUB1 as a potential therapeutic target for intractable chemotherapy resistant CRPC including AR variant driven CRPC, which lacks durable treatment options.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available